ARUP LABORATORIES | A nonprofit enterprise of the University of Utah and its Department of Pathology

Effective Date: October 20, 2025

TEST CHANGE

Haloperidol

0099640, HALO

Specimen Requirements:	
Patient Preparation:	Timing of specimen collection: Pre-dose (trough) draw?-? ~~-~~ At steady state concentration.
Collect:	Plain red. Also acceptable: Lavender (K 2~~K2~~ or K 3 EDTA~~K3EDTA~~) or pink (K 2 EDTA~~K2EDTA~~).
Specimen Preparation:	Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Remarks:	
Stability:	After separation from cells: Ambient: 4 hours; Refrigerated: 1 week; Frozen: 1 month (avoid repeated freeze/thaw cycles)
Methodology:	Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed:	Mon, Wed, Fri
Reported:	1-7 days
Note:	
CPT Codes:	80173
New York DOH Approval Status:	This test is New York DOH approved.

Interpretive Data:

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to haloperidol therapy may include drowsiness, blurred vision, tardive dyskinesia, tachycardia, hypotension, and muscular rigidity.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA -certified laboratory and is intended for clinical purposes.

Reference Interval:

Therapeutic Range:	1.0-10.0 ng/mL
Toxic:	Greater than or equal to 15.0 ng/mL

~~Effective February 16, 2021~~

~~Therapeutic Range:~~	~~5.0-20.0 ng/mL~~
~~Toxic:~~	~~Greater than 50 ng/mL~~

Inserted Cells